ReviewClinical interventions in aging2013
A review of minodronic acid hydrate for the treatment of osteoporosis.
Review in Clinical interventions in aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Osteoporosis: molecular pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Strategic Methodologies for Efficient Synthesis of Imidazo[1,5-ACS organic & inorganic Au · 2025Article
- Impact of osteopenia and osteosarcopenia on the outcomes after surgery of hepatobiliary-pancreatic cancers.Frontiers in oncology · 2024Article
- Molecular Iodine-Catalyzed Synthesis of Imidazo[1,2-ACS omega · 2022Article
- Impact of the preoperative bone mineral density on the outcomes after resection of pancreatic cancer.Surgery today · 2020Article
- Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.BMC women's health · 2020Article
- BClACS omega · 2019Article
- Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma.World journal of surgery · 2019Article
- Recent advances on the transition-metal-catalyzed synthesis of imidazopyridines: an updated coverage.Beilstein journal of organic chemistry · 2019Review
- Minodronate for the treatment of osteoporosis.Therapeutics and clinical risk management · 2018Review
- Management of Osteoporosis in Chronic Kidney Disease.Internal medicine (Tokyo, Japan) · 2017Review
- Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene.International journal of women's health · 2017Article
- Osteoporosis in East Asia: Current issues in assessment and management.Osteoporosis and sarcopenia · 2016Review
- Crystal structure of zwitterionic 3-(2-hy-droxy-2-phospho-nato-2-phosphono-eth-yl)imidazo[1,2-a]pyridin-1-ium monohydrate (minodronic acid monohydrate): a redetermination.Acta crystallographica. Section E, Crystallographic communications · 2015Article
- Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate is 1000 times more effective than etidronic acid and 10-100 times more effective than alendronic acid. Clinical trials conducted to date have focused on postmenopausal female patients suffering from primary osteoporosis. In these trials, 1 mg of oral minodronic acid hydrate was administrated once daily, and a significant increase was observed in lumbar-spine and hip-joint bone density 1-2 years after administration. All markers of bone metabolism urinary collagen type 1 cross-linked N-telopeptide, urinary free deoxypyridinoline, serum bone alkaline phosphatase, and serum osteocalcin were decreased. The incidence rate of new vertebral and nonvertebral fractures was also decreased. Therefore, effectiveness in fracture prevention was confirmed. A form of minodronic acid (50 mg) requiring once-monthly administration has been developed and is currently being used clinically. A comparative study between this new formulation and once-daily minodronic acid (1 mg) showed no significant differences between the two formulations in terms of improvement rates in lumbar-spine and hip-joint bone density, changes in bone metabolism markers, or incidence of side effects. This indicates the noninferiority of the monthly formulation. Side effects such as osteonecrosis of the jaw or atypical femoral fractures were not reported with other bisphosphonates, although it is believed that these side effects may emerge as future studies continue to be conducted. On the basis of studies conducted to date, minodronic acid hydrate is considered effective for improving bone density and preventing fractures. We anticipate further investigations in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.